Standex International (SXI) Q2 2025 earnings summary

Executive summary

• Achieved record adjusted operating margin of 18.7% in Q2 FY25, with net sales up 6.4% year-over-year to $189.8M, the highest since the 2020 divestiture, driven by acquisitions despite organic declines.

• Amran/Narayan Group acquisition, the largest in company history, exceeded sales expectations and contributed significantly to fast-growth market sales, now over 20% of total.

• New product sales more than doubled year-over-year to $14.5M, with over a dozen launches planned for FY25 and expected to add 200 basis points of incremental growth.

• Major acquisitions also included Nascent Technology and Custom Biogenic Systems, expanding presence in electrical grid and life sciences markets.

• Backlog under one year rose 14.1% to $238.9M, primarily from Electronics segment acquisitions.

Financial highlights

• Q2 FY25 net sales: $189.8M (+6.4% YoY); adjusted operating income: $35.5M (+15.4% YoY); adjusted EPS: $1.91 (flat YoY); adjusted net income: $22.9M (+1.0% YoY).

• Free cash flow was $2.2M, down sharply due to ~$11M in one-time acquisition-related payments.

• GAAP net income from continuing operations: $1.3M (-93.2% YoY); GAAP diluted EPS: $0.07 (-95.7% YoY).

• Adjusted EBITDA: $39.6M (+13.2% YoY); adjusted EBITDA margin: 20.9% (+130 bps YoY).

• Q2 gross margin: 40.9% (+60 bps YoY); operating margin: 4.5% (down from 14.5% YoY).

Outlook and guidance

• Q3 FY25 expected to see moderately to significantly higher revenue and slightly to moderately higher adjusted operating margin, led by Amran/Narayan and Electronics demand.

• FY25 sales into fast-growth markets projected at $170M, with a target of over $340M by 2028, representing more than 30% of total sales.

• Updated FY28 targets: sales >$1.15B, adjusted operating margin >23%, ROIC >15.5%.

• FY25 capex expected at $30M–$35M; Q3 interest expense projected at $7M–$7.5M.

• Productivity initiatives and new product launches expected to support further improvement in key financial metrics.